RxDoctor Payments Data

Jorge Caballero, DO

Family Medicine · Jacksonville, FLNPI 1356383384

Payments from drug & device makers

$7,246in general payments, 2019–2025

Across 471 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$1K
  • Novo Nordisk$985
  • Johnson & Johnson$400
  • Lilly USA, LLC$363
  • AstraZeneca$325
  • plus $3K from 48 others

What the payments were for

  • Food & beverage$7,233100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,246 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$158,990
Medicare patients
370
Services billed
3,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$114,153
EliquisApixaban67$93,300
FarxigaDapagliflozin Propanediol85$89,714
OzempicSemaglutide78$84,389
JanuviaSitagliptin Phosphate52$66,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$54,626
Repatha SureclickEvolocumab30$35,220
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$24,504
RybelsusSemaglutide17$22,566
ProliaDenosumab11$19,136
RexultiBrexpiprazole12$17,756
LinzessLinaclotide12$16,494
MyrbetriqMirabegron11$15,144
MounjaroTirzepatide11$12,015
SymbicortBudesonide/Formoterol Fumarate22$11,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$325$125,389136 claims
Boehringer IngelheimJardiance$115$114,153107 claims
Novo NordiskOzempic, Rybelsus$985$106,95695 claims
PfizerEliquis$249$93,30067 claims
MerckJanuvia$45$66,74552 claims
GSKTrelegy Ellipta$1,301$54,62641 claims
AbbVieLinzess, Synthroid$1,153$19,84349 claims
AmgenProlia$211$19,13611 claims
Otsuka America Pharmaceutical, Inc.Rexulti$156$17,75612 claims
Astellas Pharma US IncMyrbetriq$166$15,14411 claims
Lilly USA, LLCMounjaro$363$12,01511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →